DrugMapper


Trade Names:	EVZIO EVZIO (AUTOINJECTOR) NALOXONE NALOXONE HCL NALOXONE HYDROCHLORIDE NARCAN
Synonyms:	Anhydrous naloxone hydrochloride EN-15304 Evzio Evzio (autoinjector) Kloxxado Nalone Naloxone Naloxone hcl Naloxone hydrochloride Naloxone hydrochloride anhydrous Narcan Narcan neonatal Narcanti Narconil NIH 7890 NSC-757109 Prenoxad
Status:	Approved (1971)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	F850569PQR
Parent Compound:	NALOXONE


InChI Key	RGPDIGOSVORSAK-STHHAXOLSA-N
Smile	C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl
InChI	InChI=1S/C19H21NO4.ClH/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11;/h2-4,14,17,21,23H,1,5-10H2;1H/t14-,17+,18+,19-;/m1./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C19H22ClNO4
Molecular Weight	363.84
AlogP	1.3
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	2.0
Polar Surface Area	70.0
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	24.0

Action	Mechanism of Action	Reference
ANTAGONIST	Opioid receptors; mu/kappa/delta antagonist	PubMed FDA

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Short peptide receptor (family A GPCR) Opioid receptor	-	4-6	-	-	60
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	112

Mesh Heading	Maximum Phase	Mesh ID	Reference
Constipation	3	D003248	ClinicalTrials
Intestinal Obstruction	3	D007415	ClinicalTrials
Gambling	2	D005715	ClinicalTrials
Opioid-Related Disorders	1	D009293	ClinicalTrials

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Mixture

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	20.96
Psychiatric disorders	19.87
Nervous system disorders	15.11
Injury, poisoning and procedural complications	11.0
Gastrointestinal disorders	8.68
Cardiac disorders	4.89
Respiratory, thoracic and mediastinal disorders	4.82
Vascular disorders	3.92
Investigations	2.12
Musculoskeletal and connective tissue disorders	2.12

Cross References

Resources	Reference
ChEBI	31892
ChEMBL	CHEMBL1718
FDA SRS	F850569PQR
PubChem	5464092
SureChEMBL	SCHEMBL41390

NALOXONE HYDROCHLORIDE

Structure

Physicochemical Descriptors

Pharmacology

Indications

Related Entries

Scaffolds

Adverse Reactions

Cross References


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70